Carlo Gambacorti-Passerini

List of Publications by Year
in descending order

242 papers	18,881 citations	20759 60 h-index	12910 131 g-index
245 all docs	245 docs citations	245 times ranked	18188 citing authors

#	Article	IF	Citations
1	A prognostic model for patients with lymphoma and COVID-19: aÂmulticentre cohort study. Blood Advances, 2022, 6, 327-338.	2.5	28
2	Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma. Blood, 2022, 139, 717-731.	0.6	22
3	Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success. American Journal of Hematology, 2022, 97, 1075-1085.	2.0	13
4	Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option. Blood Reviews, 2022, 56, 100968.	2.8	16
5	Can Similarities between the Pathogenesis of Preeclampsia and COVID-19 Increase the Understanding of COVID-19?. International Journal of Translational Medicine, 2022, 2, 186-197.	0.1	3
6	Discovery of Novel Î±-Carboline Inhibitors of the Anaplastic Lymphoma Kinase. ACS Omega, 2022, 7, 17083-17097.	1.6	7
7	Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia. American Journal of Hematology, 2022, 97, .	2.0	2
8	Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. Leukemia, 2022, 36, 1825-1833.	3.3	43
9	Identification of non-ATP-competitive Î±-carboline inhibitors of the anaplastic lymphoma kinase. European Journal of Medicinal Chemistry, 2022, 238, 114488.	2.6	3
10	Whole Exome Sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target. Haematologica, 2021, 106, 1693-1704.	1.7	40
11	Treatment patterns and clinical outcomes of tyrosine kinase inhibitors in chronicâ€phase CML in clinical practice: 3â€year European SIMPLICITY data. European Journal of Haematology, 2021, 106, 82-89.	1.1	14
12	STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma. Leukemia, 2021, 35, 1500-1505.	3.3	29
13	Impact of ETNK1 somatic mutations on phosphoethanolamine synthesis, ROS production and DNA damage. Molecular and Cellular Oncology, 2021, 8, 1877598.	0.3	3
14	Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019. Mayo Clinic Proceedings, 2021, 96, 817.	1.4	1
15	VERSO: A comprehensive framework for the inference of robust phylogenies and the quantification of intra-host genomic diversity of viral samples. Patterns, 2021, 2, 100212.	3.1	26
16	Longâ€term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosomeâ€positive leukemia resistant or intolerant to prior therapy. European Journal of Haematology, 2021, 106, 808-820.	1.1	10
17	Being a Myeloproliferative Patient in COVID-19 Era: The Mytico Study. Frontiers in Oncology, 2021, 11, 668261.	1.3	1
18	Transfusion of blood products derived from SARS-CoV-2+ donors to patients with hematological malignancies. Transfusion and Apheresis Science, 2021, 60, 103105.	0.5	3

#	Article	IF	Citations
19	COVIDâ€19 elicits an impaired antibody response against SARSâ€CoVâ€2 in patients with haematological malignancies. British Journal of Haematology, 2021, 195, 371-377.	1.2	56
20	Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosomeâ€'positive leukemias. Leukemia Research, 2021, 111, 106690.	0.4	12
21	Synergistic Drug Combinations Prevent Resistance in ALK+ Anaplastic Large Cell Lymphoma. Cancers, 2021, 13, 4422.	1.7	11
22	Letter to the Editor: SFlt-1 and PlGF Levels in Pregnancies Complicated by SARS-CoV-2 Infection. Viruses, 2021, 13, 2377.	1.5	5
23	Risk of Progression in Chronic Phase - Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation (TFR-PRO study): Preliminary Results. Blood, 2021, 138, 1476-1476.	0.6	1
24	Molecular Pathogenesis of BCR-ABL-Negative Atypical Chronic Myeloid Leukemia. Frontiers in Oncology, 2021, 11, 756348.	1.3	5
25	An Update of Safety and Efficacy Results from Phase 1 Dose-Escalation and Expansion Study of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI), in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Failing Prior TKI Therapies. Blood, 2021, 138, 309-309.	0.6	3
26	An Imatinibâ€"nonâ€responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization. Clinical Case Reports (discontinued), 2020, 8, 71-74.	0.2	1
27	The role of bosutinib in the treatment of chronic myeloid leukemia. Future Oncology, 2020, 16, 4395-4408.	1.1	26
28	ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine. Nature Communications, 2020, 11, 5938.	5.8	22
29	A fatal case of TEMPI syndrome, refractory to proteasome inhibitors and autologous stem cell transplantation. Leukemia Research, 2020, 97, 106441.	0.4	8
30	Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia. HemaSphere, 2020, 4, e497.	1.2	14
31	A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation. Journal of Clinical Medicine, 2020, 9, 3692.	1.0	2
32	Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematology,the, 2020, 7, e737-e745.	2.2	430
33	Pregnancy outcomes in patients treated with bosutinib. International Journal of Hematologic Oncology, 2020, 9, IJH26.	0.7	17
34	Phase two study of crizotinib in patients with anaplastic lymphoma kinase (<scp>ALK</scp>)â€positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy. American Journal of Hematology, 2020, 95, E319-E321.	2.0	21
35	Increased <scp>sFLTâ€1</scp>/<scp>PlGF</scp> ratio in <scp>COVID</scp>â€19: A novel link to angiotensin <scp>II</scp>â€mediated endothelial dysfunction. American Journal of Hematology, 2020, 95, E188-E191.	2.0	51
36	IL10RA Modulates Crizotinib Sensitivity in NPM1-ALK-positive Anaplastic Large Cell Lymphoma. Blood, 2020, 136, 1657-1669.	0.6	22

#	Article	IF	Citations
37	Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study. Leukemia, 2020, 34, 2125-2137.	3.3	47
38	Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation. Blood, 2020, 136, 2237-2240.	0.6	13
39	Identification of genetic polymorphisms modulating nausea and vomiting in two series of opioid-treated cancer patients. Scientific Reports, 2020, 10, 542.	1.6	4
40	Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia. Annals of Hematology, 2020, 99, 1241-1249.	0.8	9
41	Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results from the Bfore Trial. Blood, 2020, 136, 41-42.	0.6	27
42	Phase 1 Trial of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): Activity in CML Chronic Phase Patients Failing TKI Therapies Including Ponatinib. Blood, 2020, 136, 51-52.	0.6	20
43	Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study. Blood Research, 2020, 55, 139-145.	0.5	2
44	Retro-Prospective Observational Study on the Risk of Progression in Chronic Phase-Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation (TFR-PRO). Blood, 2020, 136, 21-22.	0.6	0
45	Long-Term Cardiac, Vascular, and Hypertension Safety of Bosutinib (BOS) Versus Imatinib (IMA) for Newly Diagnosed Chronic Myeloid Leukemia (CML): Results from the Bfore Trial. Blood, 2020, 136, 34-35.	0.6	3
46	ETNK1 Mutations in Atypical Chronic Myeloid Leukemia Induce a Mutator Phenotype That Can be Reverted with Phosphoethanolamine. Blood, 2020, 136, LBA-5-LBA-5.	0.6	1
47	TREATMENT PATTERNS IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKAEMIA IN ROUTINE CLINICAL PRACTICE: THE SIMPLICITY ITALIAN POPULATION. Mediterranean Journal of Hematology and Infectious Diseases, 2019, 11, e2019025.	0.5	7
48	A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib. Journal of Thoracic Oncology, 2019, 14, e257-e259.	0.5	23
49	Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. Leukemia, 2019, 33, 1835-1850.	3.3	97
50	Acute myeloid leukaemia niche regulates response to Lâ€asparaginase. British Journal of Haematology, 2019, 186, 420-430.	1.2	18
51	Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia. Journal of Cancer Research and Clinical Oncology, 2019, 145, 1589-1599.	1.2	21
52	De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways. Haematologica, 2019, 104, 1789-1797.	1.7	21
53	Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice. Haematologica, 2019, 104, 1589-1596.	1.7	58
54	Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemia. Current Medical Research and Opinion, 2019, 35, 1615-1622.	0.9	13

#	Article	IF	Citations
55	Wiskottâ€“Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma. Nature Medicine, 2019, 25, 130-140.	15.2	57
56	Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronicâ€phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY. American Journal of Hematology, 2019, 94, 46-54.	2.0	32
57	Increased Tumour Burden over a 36 Month Period in Chronic Myeloid Leukemia Patients Following Imatinib Discontinuation: Role of Digital PCR. Blood, 2019, 134, 29-29.	0.6	2
58	Longâ€term effects of crizotinib in ALKâ€positive tumors (excluding NSCLC): A phase 1b openâ€label study. American Journal of Hematology, 2018, 93, 607-614.	2.0	75
59	Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells. Neoplasia, 2018, 20, 467-477.	2.3	13
60	Î²-catenin knockdown promotes NHERF1-mediated survival of colorectal cancer cells: implications for a double-targeted therapy. Oncogene, 2018, 37, 3301-3316.	2.6	18
61	Ponatinib efficacy and safety in Philadelphia chromosomeâ€positive leukemia: final 5-year results of the phase 2 PACE trial. Blood, 2018, 132, 393-404.	0.6	392
62	Longâ€term patientâ€reported outcomes from an openâ€label safety and efficacy study of bosutinib in Philadelphia chromosomeâ€positive chronic myeloid leukemia patients resistant or intolerant to prior therapy. Cancer, 2018, 124, 587-595.	2.0	19
63	Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. Journal of Clinical Oncology, 2018, 36, 231-237.	0.8	356
64	Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling. Cancers, 2018, 10, 509.	1.7	3
65	Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review. Journal of Hematology and Oncology, 2018, 11, 143.	6.9	52
66	Lorlatinib Treatment Elicits Multiple On- and Off-Target Mechanisms of Resistance in ALK-Driven Cancer. Cancer Research, 2018, 78, 6866-6880.	0.4	69
67	Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study. Haematologica, 2018, 103, 1298-1307.	1.7	49
68	Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes. Cancers, 2018, 10, 62.	1.7	73
69	SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub. Nature Communications, 2018, 9, 2192.	5.8	66
70	Efficacy and Safety Following Dose Reduction of Bosutinib or Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia: Analysis of the Phase 3 BFORE Trial. Blood, 2018, 132, 3005-3005.	0.6	7
71	Pregnancy Outcomes in Patients Treated with Bosutinib. Blood, 2018, 132, 1729-1729.	0.6	6
72	Bosutinib or Imatinib in Older Vs Younger Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Phase 3 BFORE Trial. Blood, 2018, 132, 1734-1734.	0.6	5

#	Article	IF	Citations
73	Gimema Registry of Conception/Pregnancy in Adult Italian Patients Diagnosed with Chronic Myeloid Leukemia (CML): Report on 166 Outcomes. Blood, 2018, 132, 43-43.	0.6	10
74	The Transition from Childhood to Adulthood in Chronic Immune Thrombocytopenia Patients: Clinical Management and the Role of Splenectomy and Thrombopoietin Receptor Agonists in a Single Center Experience. Blood, 2018, 132, 4987-4987.	0.6	0
75	Retaining Parental Role Despite the Presence of Hematological Neoplastic Diseases: The Emanuela Project and the Role of the Hematologist. Blood, 2018, 132, 4752-4752.	0.6	0
76	OncoScore: a novel, Internet-based tool to assess the oncogenic potential of genes. Scientific Reports, 2017, 7, 46290.	1.6	31
77	Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 684-695.e6.	0.2	42
78	Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: AÂsystematic review and a meta-analysis. European Journal of Cancer, 2017, 77, 48-56.	1.3	74
79	How â€œpreciseâ€•is precision medicine in hematology?. Haematologica, 2017, 102, 4-6.	1.7	7
80	Somatic mutations identified at diagnosis by exome sequencing can predict response to imatinib in chronic phase chronic myeloid leukemia (CML) patients. American Journal of Hematology, 2017, 92, E623-E625.	2.0	13
81	Firstâ€line treatment selection and early monitoring patterns in chronic phaseâ€chronic myeloid leukemia in routine clinical practice: SIMPLICITY. American Journal of Hematology, 2017, 92, 1214-1223.	2.0	36
82	RET kinase inhibitors: a review of recent patents (2012â€“2015). Expert Opinion on Therapeutic Patents, 2017, 27, 91-99.	2.4	19
83	The Novel PIM1 Inhibitor NMS-P645 Reverses PIM1-Dependent Effects on TMPRSS2/ERG Positive Prostate Cancer Cells And Shows Anti-Proliferative Activity in Combination with PI3K Inhibition. Journal of Cancer, 2017, 8, 140-145.	1.2	12
84	Second-Line Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia (CP CML) Resistant or Intolerant to Prior Imatinib: An 8-Year Update. Blood, 2017, 130, 900-900.	0.6	9
85	Bosutinib Vs Imatinib for Newly Diagnosed Chronic Myeloid Leukemia (CML) in the BFORE Trial: 18 Month Follow-up. Blood, 2017, 130, 896-896.	0.6	6
86	ALK inhibitors for clinical use in cancer therapy. Frontiers in Bioscience - Elite, 2016, 8, 46-60.	0.9	3
87	Longâ€term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosomeâ€positive leukemias treated with bosutinib. American Journal of Hematology, 2016, 91, 606-616.	2.0	76
88	Telomere length shortening is associated with treatment-free remission in chronic myeloid leukemia patients. Journal of Hematology and Oncology, 2016, 9, 63.	6.9	18
89	Chronic myeloid leukemia: reminiscences and dreams. Haematologica, 2016, 101, 541-558.	1.7	92
90	Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosomeâ€“positive ALL. Blood, 2016, 128, 774-782.	0.6	243

#	Article	IF	Citations
91	Chronic myeloid leukemia: Secondâ€line drugs of choice. American Journal of Hematology, 2016, 91, 67-75.	2.0	33
92	Factors influencing longâ€term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib. British Journal of Haematology, 2016, 172, 97-110.	1.2	41
93	Longâ€term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib. American Journal of Hematology, 2016, 91, 1206-1214.	2.0	90
94	Abrupt Relapse of ALK-Positive Lymphoma after Discontinuation of Crizotinib. New England Journal of Medicine, 2016, 374, 95-96.	13.9	67
95	Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency. Oncogene, 2016, 35, 3854-3865.	2.6	37
96	Oncoscore, a Novel, Internet-Based Tool to Assess the Oncogenic Potential of Genes Can Differentiate Between CP-CML and BC-CML Associated Genes, and Between CP-CML Patients with Good and Bad Prognosis. Blood, 2016, 128, 3075-3075.	0.6	1
97	Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma. Oncotarget, 2016, 7, 72886-72897.	0.8	25
98	Activity of secondâ€generation ALK inhibitors against crizotinibâ€resistant mutants in an NPMâ€ALK model compared to EML4â€ALK. Cancer Medicine, 2015, 4, 953-965.	1.3	72
99	Recurrent ETNK1 mutations in atypical chronic myeloid leukemia. Blood, 2015, 125, 499-503.	0.6	115
100	Age and d<scp>PCR</scp> can predict relapse in <scp>CML</scp> patients who discontinued imatinib: The <scp>ISAV</scp> study. American Journal of Hematology, 2015, 90, 910-914.	2.0	181
101	RNAâ€seq is a valuable complement of conventional diagnostic tools in newly diagnosed AML patients. American Journal of Hematology, 2015, 90, E227-8.	2.0	2
102	c-MYC Generates Repair Errors via Increased Transcription of Alternative-NHEJ Factors, LIG3 and PARP1, in Tyrosine Kinaseâ€“Activated Leukemias. Molecular Cancer Research, 2015, 13, 699-712.	1.5	55
103	Longâ€term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors. American Journal of Hematology, 2015, 90, 755-768.	2.0	72
104	Morgana acts as an oncosuppressor in chronic myeloid leukemia. Blood, 2015, 125, 2245-2253.	0.6	19
105	Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALKâ€“Positive Anaplastic Large Cell Lymphoma. Molecular Cancer Research, 2015, 13, 775-783.	1.5	52
106	In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib. Journal of Hematology and Oncology, 2015, 8, 81.	6.9	20
107	BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene. Molecular Cancer, 2015, 14, 132.	7.9	35
108	Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients. Experimental Hematology, 2015, 43, 1015-1018.e1.	0.2	51

#	Article	IF	Citations
109	Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients. Leukemia Research, 2015, 39, 1055-1059.	0.4	57
110	Imatinibâ€"A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015. JAMA Oncology, 2015, 1, 143.	3.4	16
111	Bosutinib versus imatinib in newly diagnosed chronicâ€phase chronic myeloid leukaemia: results from the 24â€month followâ€up of the BELA trial. British Journal of Haematology, 2015, 168, 69-81.	1.2	177
112	How <scp>I</scp> treat newly diagnosed chronic myeloid leukemia in 2015. American Journal of Hematology, 2015, 90, 156-161.	2.0	18
113	Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth. Journal of Clinical Investigation, 2015, 125, 3505-3518.	3.9	32
114	NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922. Oncotarget, 2015, 6, 5720-5734.	0.8	29
115	ETNK1 Is an Early Event and SETBP1 a Late Event in Atypical Chronic Myeloid Leukemia. Blood, 2015, 126, 3652-3652.	0.6	1
116	Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24â€month followâ€up. American Journal of Hematology, 2014, 89, 732-742.	2.0	102
117	Bosutinib: a review of preclinical and clinical studies in chronic myelogenous leukemia. Expert Opinion on Pharmacotherapy, 2014, 15, 701-710.	0.9	16
118	Crizotinib in Advanced, Chemoresistant Anaplastic Lymphoma Kinaseâ€"Positive Lymphoma Patients. Journal of the National Cancer Institute, 2014, 106, djt378.	3.0	207
119	Synthesis and biological evaluation of benzo[4,5]imidazo[1,2-c]pyrimidine and benzo[4,5]imidazo[1,2-a]pyrazine derivatives as anaplastic lymphoma kinase inhibitors. Bioorganic and Medicinal Chemistry, 2014, 22, 1303-1312.	1.4	20
120	Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Blood, 2014, 123, 1309-1318.	0.6	124
121	Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia. American Journal of Hematology, 2014, 89, 947-953.	2.0	98
122	Firstâ€line treatment of 102 chronic myeloid leukemia patients with imatinib: A longâ€term single institution analysis. American Journal of Hematology, 2014, 89, E184-7.	2.0	24
123	Current management of CML patients: Summary of the Italian Consensus Meeting held in Rome, April 11â€"12, 2013. Critical Reviews in Oncology/Hematology, 2014, 90, 181-189.	2.0	5
124	Recurrent KIT D816V Mutation in Atypical Chronic Myeloid Leukemia. Blood, 2014, 124, 3576-3576.	0.6	1
125	The Risk of Relapse in CML Patients Who Discontinued imatinib Can Be Predicted Based on Patients Age and the Results of dPCR Analysis. Blood, 2014, 124, 813-813.	0.6	4
126	Evidence of ETNK1 Somatic Variants in Atypical Chronic Myeloid Leukemia. Blood, 2014, 124, 2212-2212.	0.6	0

#	Article	IF	Citations
127	Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop. Leukemia and Lymphoma, 2013, 54, 1151-1158.	0.6	9
128	Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase. Molecular and Cellular Endocrinology, 2013, 377, 1-6.	1.6	81
129	Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood, 2013, 122, 3616-3627.	0.6	1,562
130	Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nature Genetics, 2013, 45, 18-24.	9.4	359
131	Epigenetic Silencing of the Proapoptotic Gene BIM in Anaplastic Large Cell Lymphoma through an MeCP2/SIN3a Deacetylating Complex. Neoplasia, 2013, 15, 511-IN17.	2.3	44
132	A needle in a haystack: Identifying biomarkers to personalize systemic therapy in patients with hepatocellular carcinoma. Hepatology, 2013, 57, 1291-1293.	3.6	1
133	Gene expression signature of non-involved lung tissue associated with survival in lung adenocarcinoma patients. Carcinogenesis, 2013, 34, 2767-2773.	1.3	40
134	Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors. Molecular Cancer Research, 2013, 11, 122-132.	1.5	79
135	Identification of novel point mutations in splicing sites integrating wholeâ€exome and <scp>RNA</scp>â€seq data in myeloproliferative diseases. Molecular Genetics & Genomic Medicine, 2013, 1, 246-259.	0.6	17
136	CEQer: A Graphical Tool for Copy Number and Allelic Imbalance Detection from Whole-Exome Sequencing Data. PLoS ONE, 2013, 8, e74825.	1.1	20
137	Bosutinib As Therapy For Chronic Phase Chronic Myeloid Leukemia Following Failure With Imatinib Plus Dasatinib and/Or Nilotinib: 36-Month Update. Blood, 2013, 122, 4025-4025.	0.6	1
138	FusionAnalyser: a new graphical, event-driven tool for fusion rearrangements discovery. Nucleic Acids Research, 2012, 40, e123-e123.	6.5	29
139	New developments in the treatment of ALK-driven malignancies. Clinical Investigation, 2012, 2, 835-852.	0.0	1
140	A Bioinformatics Procedure to Identify and Annotate Somatic Mutations in Whole-Exome Sequencing Data. Lecture Notes in Computer Science, 2012, , 73-82.	1.0	0
141	Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood, 2012, 119, 3403-3412.	0.6	281
142	Three novel patientâ€derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors. American Journal of Hematology, 2012, 87, E125-8.	2.0	93
143	Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial. Journal of Clinical Oncology, 2012, 30, 3486-3492.	0.8	404
144	Synergistic Effects of Combined Wnt/KRAS Inhibition in Colorectal Cancer Cells. PLoS ONE, 2012, 7, e51449.	1.1	39

#	Article	IF	Citations
145	Crizotinib in Anaplastic Large-Cell Lymphoma. New England Journal of Medicine, 2011, 364, 775-776.	13.9	256
146	Sphingosine kinase 1 overexpression is regulated by signaling through PI3K, AKT2, and mTOR in imatinib-resistant chronic myeloid leukemia cells. Experimental Hematology, 2011, 39, 653-665.e6.	0.2	37
147	Choosing the right TKI for chronic myeloid leukemia: When the truth lies in â€œlongâ€•termâ€•safety and efficacy. American Journal of Hematology, 2011, 86, 531-532.	2.0	8
148	Design, Synthesis, and Biological Activity of Urea Derivatives as Anaplastic Lymphoma Kinase Inhibitors. ChemMedChem, 2011, 6, 1680-1692.	1.6	18
149	The ALK Gene, An Attractive Target for Inhibitor Development. Current Topics in Medicinal Chemistry, 2011, 11, 1406-1419.	1.0	12
150	Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosomeâ€“positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood, 2011, 118, 4567-4576.	0.6	406
151	Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib. Journal of the National Cancer Institute, 2011, 103, 553-561.	3.0	362
152	Focal Adhesion Kinase (FAK) Binds RET Kinase via Its FERM Domain, Priming a Direct and Reciprocal RET-FAK Transactivation Mechanism. Journal of Biological Chemistry, 2011, 286, 17292-17302.	1.6	50
153	Activity of Bosutinib by Baseline and Emergent Mutation Status in Philadelphia Chromosomeâ€“Positive Leukemia Patients with Resistance or Intolerance to Other Tyrosine Kinase Inhibitors. Blood, 2011, 118, 110-110.	0.6	6
154	Safety and Management of Toxicities in the BELA Trial of Bosutinib Versus Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia. Blood, 2011, 118, 1685-1685.	0.6	9
155	Bosutinib Safety Profile and Management of Toxicities in Leukemia Patients with Resistance or Intolerance to Imatinib and Other Tyrosine Kinase Inhibitors. Blood, 2011, 118, 2760-2760.	0.6	2
156	Somatic Mutation of SF3B1, a Gene Encoding a Core Component of RNA Splicing Machinery, in Myelodysplasia with Ring Sideroblasts. Blood, 2011, 118, 3-3.	0.6	3
157	Bosutinib Versus Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia â€“ BELA Trial: 24-Month Follow-up. Blood, 2011, 118, 455-455.	0.6	9
158	ERG Deregulation Induces PIM1 Over-Expression and Aneuploidy in Prostate Epithelial Cells. PLoS ONE, 2011, 6, e28162.	1.1	25
159	Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition. Blood, 2010, 116, 3013-3022.	0.6	110
160	Synthesis, structureâ€“activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors. Bioorganic and Medicinal Chemistry, 2010, 18, 1482-1496.	1.4	64
161	Imatinib does not substantially modify the glycemic profile in patients with chronic myeloid leukaemia. Leukemia Research, 2010, 34, e5-e7.	0.4	14
162	Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-(3-thienyl)nicotinonitrile scaffold. European Journal of Medicinal Chemistry, 2010, 45, 2919-2927.	2.6	47

#	Article	IF	Citations
163	BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients. Leukemia, 2010, 24, 1445-1449.	3.3	37
164	Synergistic activity of the Src/Abl inhibitor bosutinib in combination with imatinib. Leukemia, 2010, 24, 1223-1227.	3.3	15
165	Locking Src/Abl Tyrosine Kinase Activities Regulate Cell Differentiation and Invasion of Human Cervical Cancer Cells Expressing E6/E7 Oncoproteins of High-Risk HPV. Journal of Oncology, 2010, 2010, 1-10.	0.6	36
166	Reply to P. Laneuville et al. Journal of Clinical Oncology, 2010, 28, e172-e172.	0.8	7
167	Are Chronic Myeloid Leukemia Patients More at Risk for Second Malignancies? A Population-based Study. American Journal of Epidemiology, 2010, 172, 1028-1033.	1.6	39
168	Imatinib-loaded polyelectrolyte microcapsules for sustained targeting of BCR-ABL⁺ leukemia stem cells. Nanomedicine, 2010, 5, 419-431.	1.7	33
169	Bosutinib: A review of preclinical studies in chronic myelogenous leukaemia. European Journal of Cancer, 2010, 46, 1781-1789.	1.3	62
170	Deregulated Activity and Localization of Glycogen Synthase Kinase 3Î² In Chronic Myeloid Leukemia Progenitors: Role In Leukemia Maintenance and Targeted Therapy.. Blood, 2010, 116, 1216-1216.	0.6	0
171	Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting.. Journal of Biological Chemistry, 2009, 284, 16060.	1.6	0
172	Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants. Journal of Clinical Oncology, 2009, 27, 469-471.	0.8	365
173	Mutation-Independent Anaplastic Lymphoma Kinase Overexpression in Poor Prognosis Neuroblastoma Patients. Cancer Research, 2009, 69, 7338-7346.	0.4	157
174	Valproic acid enhances bosutinib cytotoxicity in colon cancer cells. International Journal of Cancer, 2009, 124, 1990-1996.	2.3	29
175	Part I: Milestones in personalised medicineâ€"imatinib. Lancet Oncology, The, 2008, 9, 600.	5.1	51
176	BRAF Silencing by Short Hairpin RNA or Chemical Blockade by PLX4032 Leads to Different Responses in Melanoma and Thyroid Carcinoma Cells. Molecular Cancer Research, 2008, 6, 751-759.	1.5	178
177	A Mechanistic Design Principle for Protein Tyrosine Kinase Sensors:â€‰ Application to a Validated Cancer Target. Organic Letters, 2008, 10, 301-304.	2.4	16
178	Characterization of Some Molecular Mechanisms Governing Autoactivation of the Catalytic Domain of the Anaplastic Lymphoma Kinase. Journal of Biological Chemistry, 2008, 283, 3743-3750.	1.6	61
179	Characterization of compound 584, an Abl kinase inhibitor with lasting effects. Haematologica, 2008, 93, 653-661.	1.7	14
180	Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis. Blood, 2008, 111, 816-828.	0.6	44

#	Article	IF	Citations
181	Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-Î± treatment. Blood, 2008, 111, 1039-1043.	0.6	195
182	Validation of PDGFRÎ² and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib. Blood, 2008, 112, 1346-1356.	0.6	99
183	Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib. Haematologica, 2008, 93, 317-318.	1.7	32
184	Sorafenib Functions to Potently Suppress RET Tyrosine Kinase Activity by Direct Enzymatic Inhibition and Promoting RET Lysosomal Degradation Independent of Proteasomal Targeting. Journal of Biological Chemistry, 2007, 282, 29230-29240.	1.6	90
185	Oncogenic Fusion Tyrosine Kinases as Molecular Targets for Anti-Cancer Therapy. Anti-Cancer Agents in Medicinal Chemistry, 2007, 7, 594-611.	0.9	27
186	NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma. Blood, 2007, 110, 2600-2609.	0.6	34
187	The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosomeâ€negative cells. Cancer, 2007, 110, 1509-1519.	2.0	121
188	In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Nature Medicine, 2007, 13, 13-14.	15.2	54
189	Bcr-Abl stabilizes Î²-catenin in chronic myeloid leukemia through its tyrosine phosphorylation. EMBO Journal, 2007, 26, 1456-1466.	3.5	204
190	FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosomeâ€“positive acute lymphocytic leukemia. Journal of Clinical Investigation, 2007, 117, 2408-2421.	3.9	308
191	Structural Insights into the ATP Binding Pocket of the Anaplastic Lymphoma Kinase by Site-Directed Mutagenesis, Inhibitor Binding Analysis, and Homology Modeling. Journal of Medicinal Chemistry, 2006, 49, 5759-5768.	2.9	33
192	The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years. Blood Cells, Molecules, and Diseases, 2006, 37, 111-115.	0.6	9
193	A rapid method for the purification of wild-type and V804M mutant ret catalytic domain: A tool to study thyroid cancer. International Journal of Biological Macromolecules, 2006, 39, 60-65.	3.6	2
194	BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B. Blood, 2006, 107, 1591-1598.	0.6	53
195	Simultaneous development of Philadelphia chromosome-positive and -negative leukemias in the same patient. American Journal of Hematology, 2006, 81, 646-646.	2.0	7
196	Panniculitis during Dasatinib Therapy for Imatinib-Resistant Chronic Myelogenous Leukemia. New England Journal of Medicine, 2006, 354, 2623-2624.	13.9	66
197	SKI-606 Decreases Growth and Motility of Colorectal Cancer Cells by Preventing pp60(c-Src)â€“Dependent Tyrosine Phosphorylation of Î²-Catenin and Its Nuclear Signaling. Cancer Research, 2006, 66, 2279-2286.	0.4	117
198	In vitro and In vivo Activity of SKI-606, a Novel Src-Abl Inhibitor, against Imatinib-Resistant Bcr-Abl+ Neoplastic Cells. Cancer Research, 2006, 66, 11314-11322.	0.4	352

#	Article	IF	Citations
199	Inhibition of RET tyrosine kinase by SU5416. Journal of Molecular Endocrinology, 2006, 37, 199-212.	1.1	68
200	Prognostic variables in patients with chronic myeloid leukemia treated with imatinib. Haematologica, 2006, 91, 145a.	1.7	1
201	Peripheral blood progenitor cell collection in chronic myeloid leukemia patients with complete cytogenetic response after treatment with imatinib mesylate. Transfusion, 2005, 45, 1214-1220.	0.8	14
202	Evidence for D276G and L364I Bcr-Abl mutations in Ph+ leukaemic cells obtained from patients resistant to Imatinib. Leukemia, 2005, 19, 132-134.	3.3	15
203	Imatinib dose increase up to 1200â€‰mg daily can induce new durable complete cytogenetic remissions in relapsed Ph+ chronic myeloid leukemia patients. Leukemia, 2005, 19, 1985-1987.	3.3	9
204	Unique Substrate Specificity of Anaplastic Lymphoma Kinase (ALK):â€‰ Development of Phosphoacceptor Peptides for the Assay of ALK Activity. Biochemistry, 2005, 44, 8533-8542.	1.2	53
205	Expression, purification, and inhibition of human RET tyrosine kinase. Protein Expression and Purification, 2005, 41, 177-185.	0.6	30
206	Gene expression analysis fails to identify patients with chronic myeloid leukemia who will achieve cytogenetic response to imatinib. Haematologica, 2005, 90, 434.	1.7	0
207	Development of c-Kit-expressing Small-Cell Lung Cancer in a Chronic Myeloid Leukemia Patient During Imatinib Treatment. Journal of the National Cancer Institute, 2004, 96, 1723-1724.	3.0	5
208	Bcl-XL down-regulation suppresses the tumorigenic potential of NPM/ALK in vitro and in vivo. Blood, 2004, 103, 2787-2794.	0.6	30
209	PNAs as novel cancer therapeutics. International Journal of Peptide Research and Therapeutics, 2003, 10, 297-308.	0.1	2
210	Constitutive activation of Jak2 contributes to proliferation and resistance to apoptosis in NPM/ALK-transformed cells. Experimental Hematology, 2003, 31, 309-315.	0.2	59
211	Gynaecomastia in men with chronic myeloid leukaemia after imatinib. Lancet, The, 2003, 361, 1954-1956.	6.3	88
212	Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncology, The, 2003, 4, 75-85.	5.1	349
213	ALK a Novel Lymphoma-associated Tumor Antigen for Vaccination Strategies. Leukemia and Lymphoma, 2003, 44, 1675-1681.	0.6	23
214	Bcr-Abl mutations, resistance to imatinib, and imatinib plasma levels. Blood, 2003, 102, 1933-1935.	0.6	16
215	Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clinical Cancer Research, 2003, 9, 625-32.	3.2	159
216	hnRNP A1 Nucleocytoplasmic Shuttling Activity Is Required for Normal Myelopoiesis and BCR/ABL Leukemogenesis. Molecular and Cellular Biology, 2002, 22, 2255-2266.	1.1	115

#	Article	IF	Citations
217	Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood, 2002, 99, 1928-1937.	0.6	943
218	ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1â€“restricted CD8+ T-cell epitopes. Blood, 2002, 99, 2100-2106.	0.6	89
219	Binding of imatinib by Î±1-acid glycoprotein. Blood, 2002, 100, 367-369.	0.6	34
220	Determination of Î±-1 Acid Glycoprotein in Patients with Ph+ Chronic Myeloid Leukemia during the First 13 Weeks of Therapy with STI571. Blood Cells, Molecules, and Diseases, 2002, 28, 75-85.	0.6	52
221	Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia. New England Journal of Medicine, 2002, 346, 645-652.	13.9	1,899
222	Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells. Cancer Letters, 2002, 175, 17-25.	3.2	441
223	Molecular cytogenetics of the acute promyelocytic leukemia-derived cell line NB4 and of four all-trans retinoic acid-resistant subclones. Genes Chromosomes and Cancer, 2002, 35, 261-270.	1.5	14
224	BCR-ABL suppresses C/EBPÎ± expression through inhibitory action of hnRNP E2. Nature Genetics, 2002, 30, 48-58.	9.4	301
225	Sensitivity to the abl inhibitor STI571 in fresh leukaemic cells obtained from chronic myelogenous leukaemia patients in different stages of disease. British Journal of Haematology, 2001, 112, 972-974.	1.2	19
226	Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood, 2000, 95, 1758-1766.	0.6	454
227	In Vivo Eradication of Human BCR/ABL-Positive Leukemia Cells With an ABL Kinase Inhibitor. Journal of the National Cancer Institute, 1999, 91, 163-168.	3.0	341
228	In Vitro Transcriptional and Translational Block of the bcl-2 Gene Operated by Peptide Nucleic Acid. Biochemical and Biophysical Research Communications, 1999, 264, 537-543.	1.0	51
229	BCR-ABL oncoprotein is expressed by platelets from CML patients and associated with a special pattern of CrkL phosphorylation. British Journal of Haematology, 1998, 103, 1109-1115.	1.2	9
230	Inhibition of the ABL Kinase Activity Blocks the Proliferation of BCR/ABL+Leukemic Cells and Induces Apoptosis. Blood Cells, Molecules, and Diseases, 1997, 23, 380-394.	0.6	273
231	Effects of 1,25-Dihydroxy Vitamin D3 on All-Trans Retinoic Acid Sensitive and Resistant Acute Promyelocytic Leukemia Cells. Biochemical and Biophysical Research Communications, 1996, 224, 50-56.	1.0	20
232	Acute Promyelocytic Leukaemia Cells Resistant to Retinoic Acid Show Further Perturbation of the RARÎ± Signal Transduction System. Leukemia and Lymphoma, 1995, 16, 289-295.	0.6	21
233	The Role of the Immune System in Anti-Tumour Responses. Drugs and Aging, 1995, 7, 266-277.	1.3	4
234	Adoptive immunotherapy of advanced melanoma patients with interleukin-2 (IL-2) and tumor-infiltrating lymphocytes selected in vitro with low doses of IL-2. Cancer Immunology, Immunotherapy, 1993, 36, 315-322.	2.0	57

#	Article	IF	Citations
235	Immunogenicity of fusion proteins. International Journal of Clinical and Laboratory Research, 1993, 23, 186-191.	1.0	3
236	Phenotypic and functional analysis of lymphocytes infiltrating paediatric tumours, with a characterization of the tumour phenotype. Cancer Immunology, Immunotherapy, 1992, 34, 241-251.	2.0	42
237	Lysis by interleukin 2-stimulated tumor-infiltrating lymphocytes of autologous and allogeneic tumor target cells. Cancer Immunology, Immunotherapy, 1989, 28, 67-73.	2.0	19
238	Susceptibility of human and murine drug-resistant tumor cells to the lytic activity of rIL2 - activated lymphocytes (LAK). Cancer and Metastasis Reviews, 1988, 7, 335-345.	2.7	9
239	Systemic administration of autologous, alloactivated helper-enriched lymphocytes to patients with metastatic melanoma of the lung. Cancer Immunology, Immunotherapy, 1986, 21, 148-55.	2.0	27
240	Adoptive immunotherapy of cancer with immune and activated lymphocytes: Experimental and clinical studies. Research in Clinic and Laboratory, 1986, 16, 1-20.	0.3	7
241	Autologous cellular immune response to primary and metastatic human melanomas and its regulation by DR antigens expressed on tumor cells. Cancer and Metastasis Reviews, 1985, 4, 7-26.	2.7	22
242	MONOCYTE PROCOAGULANT ACTIVITY IN HYPEREOSINOPHILIC SYNDROME. Lancet, The, 1983, 322, 460-461.	6.3	3